{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:56:50Z","timestamp":1792699010185,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12325-024-02906-w","type":"journal-article","created":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T17:01:33Z","timestamp":1718557293000},"page":"3138-3158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type\u00a02 Diabetes in China"],"prefix":"10.1007","volume":"41","author":[{"given":"Jian","family":"Ming","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mernagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Pochopie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,16]]},"reference":[{"issue":"1","key":"2906_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type\u00a02 diabetes\u2014global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107\u201311.","journal-title":"J Epidemiol Glob Health"},{"key":"2906_CR2","unstructured":"China Diabetes Society. Guideline for the prevention and treatment of type\u00a02 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellitus. 2021;13:315\u2013409."},{"issue":"1","key":"2906_CR3","first-page":"15","volume":"11","author":"The Microvascular Complications Group of Chinese Diabetes Association","year":"2019","unstructured":"The Microvascular Complications Group of Chinese Diabetes Association. Chinese clinical practice guideline of diabetic kidney disease. Chin J Diabetes Mellitus. 2019;11(1):15\u201328.","journal-title":"Chin J Diabetes Mellitus"},{"issue":"2","key":"2906_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type\u00a02 diabetes. J Am Soc Nephrol. 2013;24(2):302\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2906_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3389\/fphar.2019.00480","volume":"8","author":"X Hou","year":"2019","unstructured":"Hou X, Wan X, Wu B. Cost-effectiveness of canagliflozin versus dapagliflozin added to metformin in patients with type\u00a02 diabetes in China. Front Pharmacol. 2019;8(10):480.","journal-title":"Front Pharmacol"},{"key":"2906_CR6","unstructured":"Microvascular Complications Group of Chinese Diabetes Association. Clinical Guideline for the Prevention and Treatment of Diabetic Kidney Disease in China (2021 Edition). Chin J Diabetes Mellitus. 2021;13:762\u2013784."},{"key":"2906_CR7","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes\u20142022. Diabetes Care. 2022;45(Suppl_1):S175\u201384.","DOI":"10.2337\/dc22-S011"},{"issue":"12","key":"2906_CR8","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. CJASN. 2017;12(12):2032\u201345.","journal-title":"CJASN"},{"issue":"3","key":"2906_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1159\/000489913","volume":"43","author":"K Wang","year":"2018","unstructured":"Wang K, Hu J, Luo T, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(3):768\u201379.","journal-title":"Kidney Blood Press Res"},{"issue":"23","key":"2906_CR10","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"2906_CR11","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type\u00a02 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"Suppl 20","key":"2906_CR12","doi-asserted-by":"publisher","first-page":"S375","DOI":"10.37765\/ajmc.2021.88808","volume":"27","author":"M Pochopien","year":"2021","unstructured":"Pochopien M, Cherney D, Folkerts K, et al. FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type\u00a02 diabetes. Am J Manag Care. 2021;27(Suppl 20):S375\u201382.","journal-title":"Am J Manag Care"},{"issue":"5","key":"2906_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","volume":"63","author":"LA Inker","year":"2014","unstructured":"Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713\u201335.","journal-title":"Am J Kidney Dis"},{"key":"2906_CR14","unstructured":"Chen Z, Lan X, Niehe Z, et al. Level of adipocyte fatty acid binding protein in patients with type\u00a02 diabetes mellitus and chronic kidney disease and its clinical significance. Hainan Med J. 2020;429\u201333."},{"key":"2906_CR15","unstructured":"Liang X, Chen K, Mu Y. Cost and medications in type\u00a02 diabetes mellitus inpatients with chronic kidney disease. Chin J Prev Control Chron Dis. 2016;498\u2013501."},{"key":"2906_CR16","unstructured":"Koya D, Anker SD, Ruilope LM, et al. American Society of Nephrolog |Kidney Week\u2014Abstract Details (2022). https:\/\/www.asn-online.org\/education\/kidneyweek\/2022\/program-abstract.aspx?controlId=3765674. Accessed 2023 Jul 26."},{"issue":"3","key":"2906_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1634\/theoncologist.7-3-181","volume":"7","author":"LD Case","year":"2002","unstructured":"Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002;7(3):181\u20137.","journal-title":"Oncologist"},{"key":"2906_CR18","unstructured":"National Bureau of Statistics of China. China Population and Employment Statistics Yearbook 2020. http:\/\/www.stats.gov.cn\/sj\/ndsj\/2020\/indexch.htm. Accessed 2023 May\u00a019."},{"key":"2906_CR19","unstructured":"National Health Commission of the People\u2019s Republic of China. Health Statistical Yearbook 2021. http:\/\/www.nhc.gov.cn\/mohwsbwstjxxzx\/tjtjnj\/202305\/304a301bfdb444afbf94b1a6c7f83bca.shtml. Accessed 2023 May\u00a019."},{"issue":"2","key":"2906_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s12325-020-01607-4","volume":"38","author":"O Darlington","year":"2021","unstructured":"Darlington O, Dickerson C, Evans M, et al. Costs and healthcare resource use associated with risk of cardiovascular morbidity in patients with chronic kidney disease: evidence from a systematic literature review. Adv Ther. 2021;38(2):994\u20131010.","journal-title":"Adv Ther"},{"issue":"10","key":"2906_CR21","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1093\/ndt\/gfn222","volume":"23","author":"SJ Hwang","year":"2008","unstructured":"Hwang SJ, Lin MY, Chen HC, et al. Increased risk of mortality in the elderly population with late-stage chronic kidney disease: a cohort study in Taiwan. Nephrol Dial Transpl. 2008;23(10):3192\u20138.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"2906_CR22","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jacc.2012.12.034","volume":"61","author":"KF Erickson","year":"2013","unstructured":"Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol. 2013;61(12):1250\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2906_CR23","first-page":"11","volume":"9","author":"L Zuo","year":"2018","unstructured":"Zuo L, Liu XL, Han S. Research of economic burden of CKD patients with anemia in China. China J Pharm Econ. 2018;9:11\u20136.","journal-title":"China J Pharm Econ"},{"issue":"2","key":"2906_CR24","first-page":"121","volume":"21","author":"WY Wang","year":"2018","unstructured":"Wang WY, Liang H, Lu W. Analysis on treatment burden of end-stage renal disease patients and related policy suggestions. Chin Health Resour. 2018;21(2):121\u20136.","journal-title":"Chin Health Resour"},{"issue":"2","key":"2906_CR25","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.kisu.2020.09.001","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network (CK-NET) 2016 annual data report. Kidney Int Suppl. 2020;10(2):e97\u2013185.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"2906_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5582\/bst.2017.01244","volume":"12","author":"F Li","year":"2018","unstructured":"Li F, Zhu B, He Z, et al. Exploring the determinants that influence end-of-life hospital costs of the elderly in Shanghai, China. BioSci Trends. 2018;12(1):87\u201393.","journal-title":"BioSci Trends"},{"key":"2906_CR27","doi-asserted-by":"publisher","first-page":"S476","DOI":"10.1016\/j.jval.2018.09.2809","volume":"21","author":"F Ma","year":"2018","unstructured":"Ma F, Hu C, van Haalen H, Hu R, Zhao Q, Xu L. PUK11-economic burden of chronic kidney disease related complications and therapies in china: quantifying the costs of cardiovascular events, blood transfusion for anemia and dialysis. Value Health. 2018;21:S476.","journal-title":"Value Health"},{"key":"2906_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14737167.2019.1661777","volume":"20","author":"X Duan","year":"2020","unstructured":"Duan X, Li Y, Liu Q, et al. Epidemiological characteristics, medical costs and healthcare resource utilization of diabetes-related complications among Chinese patients with type\u00a02 diabetes mellitus. Expert Rev Pharmacoecon Outcomes Res. 2020;20:513\u201321.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"14","key":"2906_CR29","first-page":"21","volume":"13","author":"H Yuan","year":"2015","unstructured":"Yuan H. Analysis of complications of type\u00a02 diabetes in patients with treatment costs. Guide China Med. 2015;13(14):21\u20132.","journal-title":"Guide China Med"},{"key":"2906_CR30","first-page":"52","volume":"12","author":"S Xuan","year":"2017","unstructured":"Xuan S, Wang S, Sun Q, et al. Real world retrospective chart review study of the hospitalization costs and associated risk factors for heart failure patients in China. China Health Insurance. 2017;12:52\u20136.","journal-title":"China Health Insurance"},{"issue":"4","key":"2906_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662\u20139.","journal-title":"Value Health"},{"key":"2906_CR32","doi-asserted-by":"crossref","unstructured":"Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36). https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta8360\/. Accessed  2023 Jul 26.","DOI":"10.3310\/hta8360"},{"key":"2906_CR33","unstructured":"National Bureau of Statistics of China. Statistic report on national economic and social development in 2022. https:\/\/www.gov.cn\/xinwen\/2023-02\/28\/content_5743623.htm. Accessed  2023 Jul 6."},{"issue":"8","key":"2906_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40273-020-00915-5","volume":"38","author":"M Paulden","year":"2020","unstructured":"Paulden M. Why it\u2019s time to abandon the ICER. Pharmacoeconomics. 2020;38(8):781\u20134.","journal-title":"Pharmacoeconomics"},{"key":"2906_CR35","doi-asserted-by":"crossref","unstructured":"Brenner BM, Cooper ME, De Zeeuw, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","DOI":"10.1056\/NEJMoa011161"},{"issue":"8","key":"2906_CR36","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3111\/13696998.2013.809352","volume":"16","author":"M Willis","year":"2013","unstructured":"Willis M, Asseburg C, He J. Validation of economic and health outcomes simulation model of type\u00a02 diabetes mellitus (ECHO-T2DM). J Med Econ. 2013;16(8):1007\u201321.","journal-title":"J Med Econ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02906-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02906-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02906-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T19:11:12Z","timestamp":1721675472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02906-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,16]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2906"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02906-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,16]]},"assertion":[{"value":"6 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jian Ming and Guanqi Hong are current employees of IQVIA, which received funds from Bayer Healthcare Company for this study. Micha\u0142 Pochopie\u0144 is an employee of Assignity. Yingrui Xu and Paul Mernagh are employees of Bayer Healthcare Company Ltd. Hongchao Li, and all other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}